Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Project IMPACT: CHW Intervention (IMPACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03159533
Recruitment Status : Completed
First Posted : May 18, 2017
Last Update Posted : May 18, 2020
Sponsor:
Information provided by (Responsible Party):
NYU Langone Health

Brief Summary:
The proposed study "Project IMPACT: CHW Intervention" is part of a larger study examining the efficacy, adoption, and impact of integrated EHR-based decision-support and physician feedback interventions with community health worker (CHW)-led self-management and coaching support for South Asian patients with uncontrolled hypertension. This is a randomized control intervention utilizing community health worker (CHW)-led self-management and coaching support for South Asian patients with uncontrolled hypertension at PCP clinics in New York City.

Condition or disease Intervention/treatment Phase
Hypertension Behavioral: CHW Intervention Behavioral: Wait List Control Group Not Applicable

Detailed Description:

The Goal of this study is that:

  1. EHR-based decision support and performance feedback interventions will be more effective in improving hypertension control for South Asian patients than standard care;
  2. A combined EHR-CHW intervention will be more effective in improving hypertension control for South Asian patients compared to standard care and the EHR-based intervention

Investigators hope to implement and assess the efficacy of CHW-led coaching through promotion of team-based care and use of culturally tailored education to improve hypertension control and mitigate risk factors related to CVD among South Asian patients with uncontrolled hypertension. Study findings can provide translatable and scalable models for other limited English proficient communities.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 305 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Step wedge design, whereby 5 groups of 3 practices will implement the intervention in phases.
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Project IMPACT: Community Health Care Worker (CHW) Intervention
Actual Study Start Date : March 9, 2017
Actual Primary Completion Date : July 1, 2019
Actual Study Completion Date : July 1, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: CHW Intervention
CHW lead Sessions Session1: BP and the Cardiovascular System Session 2: Nutrition and food labels Session 3: Physical Activity and Stress Management Session 4: CVD Risk factors: cholesterol, blood sugar, & Smoking Session 5: Health Communication, Healthcare access & Review
Behavioral: CHW Intervention
Patients randomized to Group A will be invited to attend 4 more group educational sessions on self-management immediately.CHWs will follow up with participants by phone or in person through a home or clinic visit. At these follow-up meetings, CHWs will engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to hypertension control as identified jointly by the patient and CHW. CHWs will also collect height, weight, and blood pressure measurements at initial and in-person follow-up visits. The CHW will make necessary referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.).

Placebo Comparator: Control Group
Wait-list
Behavioral: Wait List Control Group
4 education sessions beginning 6-12 months later.




Primary Outcome Measures :
  1. Percent of current diagnosed hypertensive patients with BP <140/90 (or BP<130/80 for patients with diabetes) at 6 Months [ Time Frame: 6 Months ]
  2. Percent of current diagnosed hypertensive patients with BP <140/90 (or BP<130/80 for patients with diabetes) at 12 months [ Time Frame: 12 months ]
  3. Percent of patients with HbA1c <7 (for patients with hypertension + diabetes) at 6 months [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Percent of patients with diagnosis of hypertension with a BP measure taken in the past 6 months [ Time Frame: 6 months ]
  2. Percent of patients without hypertension having valid BP measurement, last 12 months [ Time Frame: 12 months ]
  3. Percent of current hypertensive patients screened for diabetes in last year [ Time Frame: 12 months ]
  4. Percent of current hypertensive patients receiving counseling on BMI, diet and physical activity [ Time Frame: 12 months ]
  5. Percent of current diagnosed hypertensive patients referred to a nutritionist in the past year [ Time Frame: 12 months ]
  6. Percent of current diagnosed hypertensive patients who smoke who have been referred for smoking cessation [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

CHW Intervention

  • Diagnosis of hypertension or at least two systolic blood pressure measurements of 140 mm Hg or greater, or at least two diastolic BP 90 mm Hg or greater in the past 12 months.

Focus Group

  • Any clinical patients meeting the inclusion criteria for the CHW Intervention who participated in the CHW Intervention Pilot Round.

Exclusion Criteria:

  • Pregnant patients are excluded.
  • No children or vulnerable subjects will be enrolled in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03159533


Locations
Layout table for location information
United States, New York
New York University School of Medicine
New York, New York, United States, 10016
Sponsors and Collaborators
NYU Langone Health
Investigators
Layout table for investigator information
Principal Investigator: Nadia Islam NYU Langone Health
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: NYU Langone Health
ClinicalTrials.gov Identifier: NCT03159533    
Other Study ID Numbers: 16-00969
First Posted: May 18, 2017    Key Record Dates
Last Update Posted: May 18, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases